Avience maintains FY27 growth target above 50% on orders
Key highlights
- Avience reported H1 revenue of Rs 13.13 crore and maintained a FY27 growth target above 50%.
- Avience cited Rs 47 crore of government orders, with about Rs 2.5 crore executed and Rs 20-22 crore potentially executable by March.
- Management said H2 revenue would definitely exceed Rs 50 crore, while exports may contribute Rs 6-7 crore.
- Avience expects manufacturing to represent 40% of FY27 revenue and 50% in the following year.
powered by IRIS

Avience maintained its FY27 growth target of more than 50% despite H1 revenue of Rs 13.13 crore, with management citing Rs 47 crore of government orders, expected execution of Rs 20-22 crore by March and possible export revenue of Rs 6-7 crore as the basis for a sharp second-half ramp.
Know Avience Biomedicals inside out
Results, valuation, peers and who's buying, in one view.
Can Avience achieve more than 50% growth in FY27?
Avience said it can grow by 50% or more in FY27, but management’s outlook requires a substantial acceleration after H1 revenue of Rs 13.13 crore. Asked whether the new manufacturing facility would start during the year, management said its earlier commitment would be fulfilled through the existing facility together with the new facility.
The contrast is between the first-half result and management’s stated second-half expectation. An analyst said H1 revenue had grown only 16% year on year and asked how growth above 50% could be achieved. Management replied that H2 revenue would definitely be more than Rs 50 crore, but it did not provide the revenue base used to calculate the FY27 growth target in this exchange.
Management’s explanation relies on converting identified opportunities rather than extending the 16% H1 growth rate. It described Rs 20-22 crore of execution by March from government orders and referred separately to around Rs 8 crore from another source in its incremental-revenue explanation. Management said these contributions could add about Rs 28 crore of revenue and support growth above 50%.
What will drive Avience’s second-half revenue?
Avience said government-order execution and exports are the two main contributors it expects to support H2 revenue above Rs 50 crore. Of the Rs 47 crore government-order pipeline, management said about Rs 2.5 crore had already been executed and around Rs 20-22 crore more could be executed by March.
Exports were presented as a possible contribution rather than confirmed revenue. Management said its sons were focusing significantly on export business and held an optimistic view that export revenue of approximately Rs 6-7 crore may come in. The distinction is material because the government component was described as orders, while the export estimate was framed as an anticipated sales outcome.
Avience is also pursuing government business beyond the orders supporting its second-half plan. Management said it was in discussions with the Delhi, Andhra Pradesh and Odisha governments and was exploring Uttar Pradesh. It separately disclosed an Andhra Pradesh government order of about Rs 1.5 crore for HIV kits, covering one product.
The plan therefore depends on delivery against the Rs 47 crore order pipeline and on export sales materialising. Management’s Rs 20-22 crore estimate for execution by March is below the full order-pipeline value, so the remaining amount was not presented as H2 revenue during the call. No customer, timing or order-status details were given for the anticipated Rs 6-7 crore of exports.
Got a follow-up? Ask IRIS
How will Avience’s manufacturing mix change?
Avience expects manufacturing to account for approximately 40% of FY27 revenue and trading for the remaining 60%, before reaching a 50-50 split in the following year. Management linked the shift to the existing facility and the planned new manufacturing facility.
Avience currently manufactures semi-automatic analyzers, which management said are suited to tier-2 and tier-3 cities and smaller customers rather than large hospitals and laboratories with high sample volumes. Fully automated analyzers were under validation, and management said they could start 2-3 months after the new manufacturing facility receives its licence.
Management also described tie-ups with 2-3 manufacturers in China for high-performance liquid chromatography, or HPLC, analyzers, biochemistry analyzers and hematology analyzers. The products had arrived and were being validated at Avience’s facility. Management said Avience was adding its own inputs to meet a Make in India threshold of 25% or more local input, while manufacturing all reagents at its facility.
What margin change does Avience expect from expansion?
Avience said earnings before interest, taxes, depreciation and amortisation, or EBITDA, could increase by 2-3% while it remains in expansion mode, with EBITDA reaching approximately 35-36% after the expansion phase ends and operations reach a stable position. These were management expectations rather than reported margins for a specified period.
Management gave two estimates during a discussion affected by connection problems. In the first response on a future 50-50 manufacturing and trading mix, it said EBITDA would increase slightly by 1-2% because expansion also increases expenses. After the question was repeated, management said the increase would be 2-3% and that a larger improvement would come one year later, after expansion was complete.
The new plant’s expected capital expenditure, or capex, has increased from the initially proposed Rs 30 crore to approximately Rs 35-40 crore. An analyst asked for a split between land, building, plant and machinery, but management did not provide one. The allocation of the additional Rs 5-10 crore, commissioning timing and the effect on operating costs therefore remained unresolved in the call.
Conclusion
Avience’s growth case combines a near-term revenue conversion plan with a longer-term change in business mix. Management expects government orders and possible exports to produce the required H2 acceleration, while manufacturing is projected to rise from 40% of revenue in FY27 to 50% in the following year.
The next disclosures to watch are execution against the Rs 47 crore government-order pipeline, the outcome of the anticipated Rs 6-7 crore export contribution and licensing for the new manufacturing facility. Management said fully automated analyzers could start 2-3 months after that licence, while the new plant’s capex estimate stands at Rs 35-40 crore.


